Literature DB >> 12718536

The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation.

John J Dwyer1, Aisha Hasan, Karen L Wilson, Jonathan M White, Thomas J Matthews, Mary K Delmedico.   

Abstract

In models of HIV fusion, the glycoprotein gp41 is thought to form a six-helix bundle during viral fusion with the target cell. This bundle is comprised of three helical regions (from the heptad repeat 2, or HR2, region of gp41) bound to an inner, trimeric, coiled-coil core (from the HR1 region). Although much has been learned about the structure and thermodynamics of this complex, the energetics of the isolated HR1 self-associated oligomer remain largely unknown. By systematically studying self-association through a series of truncations based on a 51-mer HR1 peptide (T865), we have identified amino acid segments which contribute significantly to the stability of the oligomeric HR1 complex. Biophysical characterization of C-terminal truncations of T865 identifies a 10-15-amino acid region that is essential for HR1 oligomerization. This region coincides with a hydrophobic pocket that provides important contacts for the interaction of HR2 helices. Complete removal of this pocket abolishes HR1 oligomerization. Despite the dramatic reduction in stability, the monomeric HR1 peptides are still able to form stable six-helix bundles in the presence of HR2 peptides. Truncations on the N-terminal side of T865 have little effect on oligomerization but significantly reduce the stability of the HR1-HR2 six-helix bundle. Unlike the HR2 binding site, which extends along a hydrophobic groove on the HR1 oligomer, the residues that are critical for HR1 oligomerization are concentrated in a 10-15-amino acid region. These results demonstrate that there are localizations of binding energy, or "hot spots", in the self-association of peptides derived from the HR1 region of gp41.

Mesh:

Substances:

Year:  2003        PMID: 12718536     DOI: 10.1021/bi027283n

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  23 in total

1.  Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket.

Authors:  Xiaowen Yu; Lu Lu; Lifeng Cai; Pei Tong; Suiyi Tan; Peng Zou; Fanxia Meng; Ying-Hua Chen; Shibo Jiang
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

2.  Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.

Authors:  Elisabetta Bianchi; Marco Finotto; Paolo Ingallinella; Renee Hrin; Anthony V Carella; Xiaoli S Hou; William A Schleif; Michael D Miller; Romas Geleziunas; Antonello Pessi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-29       Impact factor: 11.205

3.  Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.

Authors:  John J Dwyer; Karen L Wilson; Donna K Davison; Stephanie A Freel; Jennifer E Seedorff; Stephen A Wring; Nicolai A Tvermoes; Thomas J Matthews; Michael L Greenberg; Mary K Delmedico
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-19       Impact factor: 11.205

4.  Design of an engineered N-terminal HIV-1 gp41 trimer with enhanced stability and potency.

Authors:  John J Dwyer; Karen L Wilson; Kimberly Martin; Jennifer E Seedorff; Aisha Hasan; Robyn J Medinas; Donna K Davison; Michael D Feese; Hans-Thomas Richter; Hidong Kim; Thomas J Matthews; Mary K Delmedico
Journal:  Protein Sci       Date:  2008-04       Impact factor: 6.725

5.  Inhibition of murine leukemia virus envelope protein (env) processing by intracellular expression of the env N-terminal heptad repeat region.

Authors:  Wu Ou; Jonathan Silver
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

6.  Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120.

Authors:  Emmanuel Desmezieres; Nidhi Gupta; Russell Vassell; Yong He; Keith Peden; Lev Sirota; Zhongning Yang; Paul Wingfield; Carol D Weiss
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

7.  Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors.

Authors:  Zhi Qi; Weiguo Shi; Na Xue; Chungen Pan; Weiguo Jing; Keliang Liu; Shibo Jiang
Journal:  J Biol Chem       Date:  2008-07-28       Impact factor: 5.157

Review 8.  Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41.

Authors:  Lu Lu; Fei Yu; Lifeng Cai; Asim K Debnath; Shibo Jiang
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

9.  Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors.

Authors:  Yuxian He; Jianwei Cheng; Jingjing Li; Zhi Qi; Hong Lu; Mingxin Dong; Shibo Jiang; Qiuyun Dai
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

10.  Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.

Authors:  Josh D Nelson; Heather Kinkead; Florence M Brunel; Dan Leaman; Richard Jensen; John M Louis; Toshiaki Maruyama; Carole A Bewley; Katherine Bowdish; G Marius Clore; Philip E Dawson; Shana Frederickson; Rose G Mage; Douglas D Richman; Dennis R Burton; Michael B Zwick
Journal:  Virology       Date:  2008-05-21       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.